Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

1535008

USP

Phenytoin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

5,5-Diphenylhydantoin, 5,5-Diphenyl-2,4-imidazolidinedione, Phenytoin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12N2O2
CAS Number:
57-41-0
Molecular Weight:
252.27
Beilstein:
384532
MDL number:
MFCD00005264
UNSPSC Code:
41116107
PubChem Substance ID:
329750826
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

phenytoin

manufacturer/tradename

USP

mp

293-295 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3

InChI

1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)

InChI key

CXOFVDLJLONNDW-UHFFFAOYSA-N

Gene Information

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Phenytoin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Phenytoin Sodium
  • Phenytoin Chewable Tablets
  • Phenytoin Oral Suspension
  • Phenytoin Sodium Injection
  • Extended Phenytoin Sodium Capsules
  • Phenytoin Compounded Topical Gel
  • Fosphenytoin Sodium Injection

Biochem/physiol Actions

Anticonvulsant.
Reduces incidence of grand mal seizures; appears to stabilize excitable membranes perhaps through effects on Na+, K+, and Ca2+ channels.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Disclaimer

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1535019

Phenytoin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1535507

Phenytoin sodium, United States Pharmacopeia (USP) Reference Standard

1535020

Phenytoin Related Compound B, United States Pharmacopeia (USP) Reference Standard

P1290000

Phenytoin, European Pharmacopoeia (EP) Reference Standard

P1300000

Phenytoin sodium, European Pharmacopoeia (EP) Reference Standard

Y0001167

Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard

PHR1492

Phenytoin sodium, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1574

Phenytoin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1692

Phenytoin Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

BP1238

Phenytoin sodium, British Pharmacopoeia (BP) Reference Standard

PHR2246

1-Methyl-5,5-diphenylimidazolidine-2,4-dione, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9055

Benzil, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

PHR2247

5-(4-Methylphenyl)hydantoin

PHR2553

Phenytoin Impurity F, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H351,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Carc. 2 - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

PRTR

Class I Designated Chemical Substances

ISHL Indicated Name

Substances Subject to be Indicated Names

ISHL Notified Names

Substances Subject to be Notified Names

JAN Code

1535008-200MG:

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Deborah Pugin et al.
Critical care (London, England), 18(3), R103-R103 (2014-06-03)
Seizures refractory to third-line therapy are also labeled super-refractory status epilepticus (SRSE). These seizures are extremely difficult to control and associated with poor outcome. We aimed to characterize efficacy and side-effects of continuous infusions of pentobarbital (cIV-PTB) treating SRSE. We
Chunhong Shen et al.
Bone, 64, 246-253 (2014-05-02)
It has been shown that antiepileptic drugs (AEDs) may have a detrimental effect on bone health and translate into an increased risk of bone fracture. We aimed to comprehensively evaluate the association between use of AEDs and fracture risk. We
Syed Nabeel Zafar et al.
BMC neurology, 12, 30-30 (2012-05-31)
Current standard therapy for seizure prophylaxis in Neuro-surgical patients involves the use of Phenytoin (PHY). However, a new drug Levetiracetam (LEV) is emerging as an alternate treatment choice. We aimed to conduct a meta-analysis to compare these two drugs in
Lelia Duley et al.
The Cochrane database of systematic reviews, (10)(10), CD000128-CD000128 (2010-10-12)
Eclampsia, the occurrence of a seizure in association with pre-eclampsia, remains a rare but serious complication of pregnancy. A number of different anticonvulsants have been used to control eclamptic fits and to prevent further seizures. The objective of this review
P J Smith et al.
Endocrine reviews, 5(4), 514-524 (1984-01-01)
The studies described above indicate the likelihood of a significant effect of DPH on cellular functions that are regulated by T3 at concentrations of DPH that occur during treatment of patients with Dilantin. Thus, it is possible that sensitive measures
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service